Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: A position statement of the Korean diabetes association

behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

doi:10.4093/dmj.2017.41.6.423

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: A position statement of the Korean diabetes association

behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

Chungnam National University
Gwangmyeong Sungae Hospital
The Catholic University of Korea
Kyung Hee University
Sungkyunkwan University
Korea University
Seoul National University
Yonsei University
Chosun University
Inje University
Hallym University
Chung-Ang University
Kangbuk Samsung Hospital
Taeyoung 21 Hospital
Kim HJ Medical Clinic

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Original language	English
Pages (from-to)	423-429
Number of pages	7
Journal	Diabetes and Metabolism Journal
Volume	41
Issue number	6
DOIs	https://doi.org/10.4093/dmj.2017.41.6.423
State	Published - 1 Dec 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cardiovascular benefit
Clinical practice guideline
Combination therapy
Glucagon-like peptide-1 receptor agonist
Hypoglycemia
Monotherapy

Access to Document

10.4093/dmj.2017.41.6.423

Cite this

@article{4c6a98031ae34a1981c33cf81aebc5cc,

title = "Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: A position statement of the Korean diabetes association",

abstract = "The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.",

keywords = "Cardiovascular benefit, Clinical practice guideline, Combination therapy, Glucagon-like peptide-1 receptor agonist, Hypoglycemia, Monotherapy",

author = "\{behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association\} and Kim, \{Hyun Jin\} and Park, \{Seok O.\} and Ko, \{Seung Hyun\} and Rhee, \{Sang Youl\} and Hur, \{Kyu Yeon\} and Kim, \{Nan Hee\} and Moon, \{Min Kyong\} and Lee, \{Byung Wan\} and Kim, \{Jin Hwa\} and Choi, \{Kyung Mook\} and Kim, \{Tae Nyun\} and Lee, \{Yong ho\} and Kim, \{Jin Hwa\} and Hong, \{Eun Gyoung\} and Jaetaek Kim and Lee, \{Won Young\} and Bokrye Song and Kim, \{Ji Young\} and Yang, \{Dong Hee\} and Taeyoung Yang and Hyeongjin Kim",

note = "Publisher Copyright: {\textcopyright} 2017 Korean Diabetes Association.",

year = "2017",

month = dec,

day = "1",

doi = "10.4093/dmj.2017.41.6.423",

language = "English",

volume = "41",

pages = "423--429",

journal = "Diabetes and Metabolism Journal",

issn = "2233-6079",

publisher = "Korean Diabetes Association",

number = "6",

}

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: A position statement of the Korean diabetes association. / behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association.
In: Diabetes and Metabolism Journal, Vol. 41, No. 6, 01.12.2017, p. 423-429.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus

T2 - A position statement of the Korean diabetes association

AU - behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

AU - Kim, Hyun Jin

AU - Park, Seok O.

AU - Ko, Seung Hyun

AU - Rhee, Sang Youl

AU - Hur, Kyu Yeon

AU - Kim, Nan Hee

AU - Moon, Min Kyong

AU - Lee, Byung Wan

AU - Kim, Jin Hwa

AU - Choi, Kyung Mook

AU - Kim, Tae Nyun

AU - Lee, Yong ho

AU - Kim, Jin Hwa

AU - Hong, Eun Gyoung

AU - Kim, Jaetaek

AU - Lee, Won Young

AU - Song, Bokrye

AU - Kim, Ji Young

AU - Yang, Dong Hee

AU - Yang, Taeyoung

AU - Kim, Hyeongjin

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

AB - The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

KW - Cardiovascular benefit

KW - Clinical practice guideline

KW - Combination therapy

KW - Glucagon-like peptide-1 receptor agonist

KW - Hypoglycemia

KW - Monotherapy

UR - https://www.scopus.com/pages/publications/85038876278

U2 - 10.4093/dmj.2017.41.6.423

DO - 10.4093/dmj.2017.41.6.423

M3 - Review article

AN - SCOPUS:85038876278

SN - 2233-6079

VL - 41

SP - 423

EP - 429

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

IS - 6

ER -

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: A position statement of the Korean diabetes association

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this